Savara Presents Clinical Trial Post-Hoc Analysis Of IMPALA At CHEST 2026 Annual Meeting To Evaluate Effects Of Molgramostim In aPAP Patients
Benzinga Newsdesk 1 month ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the CHEST 2026 Annual Meeting in Phoenix, Arizona. The poster reports a
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the CHEST 2026 Annual Meeting in Phoenix, Arizona. The poster reports a post-hoc analysis of the IMPALA clinical trial evaluating the effects of molgramostim in aPAP patients with mildly decreased or normal diffusion capacity, defined as a baseline percent predicted hemoglobin-adjusted diffusing capacity of the lungs for carbon monoxide (DLco%) greater than 70%.
More on SVRA
FDA & biotech Benzinga
Savara Craters as FDA Delays Decision for Lung DiseaseSavara (NASDAQ: SVRA) shares fell Friday after the FDA said it will miss its November 22, 2026 PDUFA target date for molgramostim.

FDA & biotech Benzinga
Savara Says FDA Will Not Meet PDUFA Target Action Date Of November 22 For Molgramostim Inhalation Solution BLA For Treatment Of Autoimmune PAP; No Revised Action Date Communicated By The FDASavara Inc. (NASDAQ:SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the U.S. Food and Drug Administration (FDA) has communicated that it…
Analyst ratings Benzinga
HC Wainwright & Co. Maintains Buy on Savara, Lowers Price Target to $9HC Wainwright & Co. analyst Matthew Caufield maintains Savara (NASDAQ:SVRA) with a Buy and lowers the price target from $10 to $9.
